Reuters Health Report

Click to View in Browser 06/2/2014 Roche returns to antibiotic research as superbug threat grows ZURICH (Reuters) - Roche is betting the same tools that made it the world's largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research. E-cig advertising seen by U.S. youth on the rise NEW YORK (Reuters Health) - The amount of television advertising for electronic cigarettes that American adolescents saw jumped by more than 250 percent over the past few years, according to a new study. Aerobics for the brain? Fitness experts praise mindfulness meditation NEW YORK (Reuters) - Fitness experts call it bicep curls for the brain and aerobics for the mind. Whatever the name, athletes and gym addicts are discovering how mindfulness meditation can enliven a workout routine and invigorate a sports performance. Personalized therapy helped women with advanced cervical cancer CHICAGO (Reuters) - A new type of personalized cancer therapy in which immune cells are harvested from patients' tumors, grown in the lab and infused back into patients showed dramatic results in a small, government-led trial in women with advanced cervical cancer, U.S. researchers said on Monday. Merck immune system-booster effective in skin, lung cancer (Reuters) - A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday. Bristol's Yervoy, alone or in combo, improves melanoma results: studies (Reuters) - New data on Bristol-Myers Squibb Co's melanoma drug Yervoy, including fresh results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday. Alexion Pharma recalls certain lots of intravenous drug Soliris (Reuters) - Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain. Eye drug wins first FDA approval for Omeros, shares rise (Reuters) - Omeros Corp said the U.S. Food and Drug Administration had approved its drug for use in cataract and lens replacement surgeries, the first drug developed by the company to get marketing clearance from the regulator. FDA calculates costs of lost enjoyment if e-cigarette rules prevent smoking NEW YORK (Reuters) - As U.S. health regulators consider what rules to impose on electronic cigarettes, in their tally of costs and benefits they have placed a value on the lost pleasure consumers may suffer if they used the products less or not at all. Roche acquires DNA sequencing firm for up to $350 million ZURICH (Reuters) - Swiss drugmaker Roche said it was buying privately held U.S. gene-sequencing firm Genia Technologies for up to $350 million, securing access to a technology that should allow it to decipher human genes at a cheaper cost. Related Video Researchers see solar-powered cars on the road ahead Scans reveal snout nervous system of the mighty pliosaur The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend